Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
- PMID: 2881943
- DOI: 10.1210/jcem-64-5-896
Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
Abstract
The physiological significance of the hyperglucagonemia that occurs in patients with many catabolic conditions is unclear. The effect of hyperglucagonemia on resting metabolic rate (RMR) was studied in six normal subjects. Infusion of somatostatin (SRIH; 500 micrograms/h for 210 min) resulted in a 5-fold decrease in plasma C-peptide and a 2-fold decrease in plasma insulin and glucagon concentrations, but did not change RMR significantly. When glucagon (0.2 micrograms/kg X h), was infused with SRIH (500 micrograms/h for 210 min), the decreases in plasma C-peptide and insulin were similar to that during the infusion of SRIH alone, but plasma glucagon increased from 160 +/- 24 (+/- SEM) to 560 +/- 80 pg/mL (P less than 0.001). There was a significant increase in RMR during the entire period (210 min) of glucagon infusion (P less than 0.01). During the last hour of the glucagon plus SRIH infusion, the RMR was 1.38 +/- 0.10 Cal/min, which was 15% higher than the preinfusion RMR (1.19 +/- 0.10 Cal/min; P less than 0.01) and 14% higher than the RMR during the same period when SRIH alone was infused (1.21 +/- 0.11 Cal/min; P less than 0.01). When SRIH and glucagon were infused, protein oxidation (calculated from urinary nitrogen loss) was 52 +/- 5 mg/min, 29% higher than when SRIH alone was infused (40 +/- 5 mg/min; P less than 0.05). These results indicate that hyperglucagonemia during insulin deficiency results in an increase in energy expenditure, which may contribute to the catabolic state in many conditions.
Similar articles
-
Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate.Diabetes. 1998 Nov;47(11):1748-56. doi: 10.2337/diabetes.47.11.1748. Diabetes. 1998. PMID: 9792544
-
Somatostatin does not alter insulin-mediated glucose disposal.J Clin Endocrinol Metab. 1987 Aug;65(2):364-7. doi: 10.1210/jcem-65-2-364. J Clin Endocrinol Metab. 1987. PMID: 2885337 Clinical Trial.
-
Somatostatin infusion enhances hepatic glucose production during hyperglucagonemia.Metabolism. 1988 Mar;37(3):252-6. doi: 10.1016/0026-0495(88)90104-7. Metabolism. 1988. PMID: 2893970
-
Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.J Clin Invest. 2012 Jan;122(1):4-12. doi: 10.1172/JCI60016. Epub 2012 Jan 3. J Clin Invest. 2012. PMID: 22214853 Free PMC article. Review.
-
Methods and Guidelines for Measurement of Glucagon in Plasma.Int J Mol Sci. 2019 Oct 30;20(21):5416. doi: 10.3390/ijms20215416. Int J Mol Sci. 2019. PMID: 31671667 Free PMC article. Review.
Cited by
-
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.Drugs. 2024 Feb;84(2):127-148. doi: 10.1007/s40265-023-01982-6. Epub 2023 Dec 21. Drugs. 2024. PMID: 38127286 Review.
-
Cracking the combination: Gut hormones for the treatment of obesity and diabetes.J Neuroendocrinol. 2019 May;31(5):e12664. doi: 10.1111/jne.12664. Epub 2019 Jan 2. J Neuroendocrinol. 2019. PMID: 30466162 Free PMC article. Review.
-
Glucagon Regulation of Energy Expenditure.Int J Mol Sci. 2019 Oct 30;20(21):5407. doi: 10.3390/ijms20215407. Int J Mol Sci. 2019. PMID: 31671603 Free PMC article. Review.
-
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.Int J Mol Sci. 2019 Aug 22;20(17):4092. doi: 10.3390/ijms20174092. Int J Mol Sci. 2019. PMID: 31443356 Free PMC article. Review.
-
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century.Front Endocrinol (Lausanne). 2018 Aug 15;9:442. doi: 10.3389/fendo.2018.00442. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30158899 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical